30-31 - Viruses As Research Tools and Assay of Animal Viruses Flashcards

(36 cards)

1
Q

Name some of the useful properties of viruses which we can exploit…

A
  • Trigger immune response
  • Natural gene delivery vehicles
  • Cytopathic (cell killing) effects
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

An early example of viruses used in medicine is…

A

Viral vaccines

(Edward Jenner using cowpox to innoculated against smallpox)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Types of vaccines in general use (4)…

A
  • Live heterologous (cowpox - smallpox)
  • Live attenuated (weakened, MMR)
  • Killed whole virus (Salk vaccine for polio)
  • Subunit (purified from virus (Influenza A) or recombinant proteins (HBV, HPV))
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe host range attenuation (4)…

A
  1. Virus isolated and cultured on human cells
  2. Incubated on cells from a new host (e.g. monkey) 🙊
  3. Spontaneous mutation allows viral growth on monkey cells
  4. This virus can be used as a vaccine as it can’t grow on human cells
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

The disadvantage of killed and subunit vaccines is that they…

A

Only induce a humoral (antibody) response, when cell mediated response is often critical to an anti-viral immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

The advantage of live vaccines is that they elicit…

A

Both humoral (antibody) and cell-mediated immune response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Give two reasons why it may not be possible to make a live vaccine for a particular virus…

A
  • It can’t be grown in culture
  • It cant be attenuated to a safe level
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

A potential solution to the problems associated with live vaccines and killed/subunit vaccines is…

A

Live recombinant viral vaccines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

To create a live recombinant viral vaccine, the immunogenic gene from the pathogenic virus is…

A

Ligated into the genome of an existing viral vector

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Give examples of applications of viral vectors in research (In vitro and In vivo)

A
  • In vitro
    • Investigation of protein function
      • Express a protein not normally expressed
      • siRNA delivery to block gene expression
  • In vivo
    • To create transgenic animals 🐁
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

List 5 commonly used viral vectors…

A
  1. Bacteriophage
  2. Baculovirus
  3. Adenovirus**
  4. Pox virus (Vaccinia)*
  5. Retroviruses*

*Mammalian host cells

**Specific human host cells

Bold = safety issues

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Other than viral vaccines, give 3 further examples of viruses used as medical tools…

A
  • Gene therapy (delivery of functional gene)
  • Oncolytic therapy (targeting cancer cells)
  • Phage therapy (targeting bacterial cells in infection)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Distinguish betwen ex vivo and in vivo approaches to gene therapy…

A
  • ex vivo (outside body)
    • cells removed from body-> gene introduced -> cells returned
  • in vivo (in body)
    • gene is introduced directly into body via virus or other gene vector
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

An example of ex vivo gene therapy is…

A

CAR-T (chimeric antigen receptor T cell) therapy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Phage therapy relies on enzymes produced by some bacteriophages, known as…

A

Lysins (or endolysin) which cleaves host cell wall

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Oncolytic virotherapy is the use of a…

A

Lytic virus to destroy cancer cells

17
Q

Outline the pros and cons of virotherapy…

A
  • Pros
    • Can be combined w/ other cancer treatments
    • Excellent safety profile
    • Dual action (direct oncolysis and immune-mediated anticancer effect)
    • Alternative cell killing mechanisms - overcome resistance
  • Cons
    • Resistant cancer cells
    • Limited replication and spreading (because tumour cells must be effectively destroyed)
    • Antiviral immune response
18
Q

Oncorine

A

First oncolytic virus approved for clinical use. Genetically modified adenovirus H101 for nasopharyngeal carcinoma

19
Q

How can we detect and count viruses in the lab (2)…

A
  • Cell based assays
  • Protein based assays

(other techniques exists, but not covered in this module)

20
Q

4 Steps to growing viruses in the lab…

A
  1. Grow cells in tissue culture
  2. Infect the cells with virus
  3. Incubate and observe for effects of viral infection
  4. Harvest cells/ medium to measure viable virus particles per ml
21
Q

MOI (multiplicity of infection) ( = or ≠ )particles per cell

A

MOI (multiplicity of infection) particles per cell

22
Q

The two main types of cell-based assay are…

A
  1. Plaque assay
  2. End-Point Dilution Assay (EPDA)
23
Q

Plaque assays detect infectious virus particles. Each plaque observed represents…

A

1 viable infectious particle (PFU)

24
Q

Limitations of plaque assays…

A
  • The virus used must cause a visual cytopathic effect
  • requires 7+ days
  • requires maintainence of sterility
25
Example of a variation of the plaque assay...
**Focus Forming Assay (FFU)** * **No agar overlay** * **Immunostain** (fluroscent Ig) fixing after 24hrs * **DNA stain counterstain** counts cells * Cells and infected cells counted via **fluorescent microscopy**
26
**End-point dilution assay (EPDA)** is the second type of cell-based assay. It involves...
**Sequential dilution** of virus stock in a **microtitre plate** format. (8 x 12 =96 wells allows multiple copies at each dilution level)
27
Give an example of an EPDA...
**Tissue Culture Infectious Dose 50 (TCID50)** * Used in **drug development** (not clinically) * Can identify **non-plaquing viruses** * TCID50 = virus concentration capable of killing 50% of cells in culture
28
List the limitations of Tissue Culture Infectious Dose 50 (TCID50) end-point dilution assays...
* **Time consuming** * Labour intesive (**medium must be regularly changed**) * Prone to **drying out** * **Sterility** must be maintained
29
List the 3 **protein or biochemical-based** assays...
1. **Electron microscopy** 2. **Haemagglutination** 3. **Immunofluorescence**
30
Electron microscopy (either TEM or SEM) allows for identification of virus particles, but not...
**Infectivity**
31
Haemaglglutination measures ______ & ________ virus particles via a simple biochemical reaction.
Haemaglglutination measures **viable & non-viable** virus particles via a simple biochemical reaction.
32
Haemogglutination relies on the ability of viruses to ______________ , which results in a visual difference between wells (see image).
Haemogglutination relies on the ability of viruses to **cross-link RBCs** , which results in a visual difference between wells (see image).
33
Haemagglutination is ( specific / non-specific )
Haemagglutination is **non-specific**
34
**Immunofluorescence** is used to stain _______ on cell surface or sections of infected cells
**Immunofluorescence** is used to stain **viral antigens** on cell surface or sections of infected cells
35
Outline the 3 steps of immunofluoresence...
1. add **virus-specific antibody**\* 2. add FITC **(fluorescent) secondary antibody**\* 3. identify fluorescent loci with **UV microscope** ## Footnote \*and wash to remove unbound antibodies
36
ELISA stands for...
Enzyme Linked ImmunoSorbent Assay (and is a form of immunofluorescence)